12:42pm Friday 23 June 2017

New Study Finds Endoscopic Sleeve Gastroplasty an Effective Treatment for Some Obese Patients

Minimally invasive procedure shows promise for facilitating weight loss

Endoscopic tools. Photo Credit: Artem Z. Photographer, Illustrator / Vector Artist, Videographer, Ukraine

NEW YORK – A new weight loss procedure that reduces the size of the stomach without the need for surgery known as endoscopic sleeve gastroplasty (ESG) is safe and effective way for the treatment obesity and obesity-related comorbidities such as diabetes, high blood pressure and fatty liver, according to a new study by NewYork-Presbyterian and Weill Cornell Medicine researchers.

ESG is an incisionless, same-day outpatient procedure performed using an endoscope, a flexible instrument with an attached camera that allows the physician to visualize the stomach from outside the body. The goal of ESG is to reduce the length and width of the stomach to facilitate weight loss. NewYork-Presbyterian is currently the leading institution and the first in New York to offer this innovative treatment, and its physicians have performed the most procedures in the country.

The study will be published in the spring 2017 journal of Clinical Gastroenterology and Hepatology and is published online.

“Obesity is a significant health concern that affects millions of people across the country, but until now there hasn’t been an effective minimally invasive treatment we could offer patients,” said Dr. Reem Sharaiha, director of bariatric endoscopy and associate director of the Pancreas Program at NewYork-Presbyterian/Weill Cornell Medical Center and an assistant professor of medicine at Weill Cornell Medicine. “With ESG, we’re giving patients who are not eligible for surgery, or deemed to be too high risk for surgery a new option for their care.”

The study followed 91 patients who underwent ESG from August 2013 through March 2016. All patients were clinically obese with a body mass index (BMI) greater than 30 kg/m² and had failed non-invasive weight-loss measures, or had a BMI greater than 40 kg/m² and were not considered as surgical candidates or had refused surgery. At six months, patients in the study had lost 14.4 percent of their total body weight, 17.6 percent at 12 months and 20.9 percent loss at 24 months. In addition to sustained total body weight loss up to 24 months, ESG reduced key indicators of hypertension, diabetes and hypertriglyceridemia, a high level of a certain type of fat (triglycerides) in the blood that can predispose patients to cardiovascular disease.

Obesity is a significant public health challenge, affecting more than one-third of adults in the United States. The estimated annual health care costs of obesity-related illnesses are $190.2 billion, nearly 21 percent of annual medical spending in the U.S. It is strongly associated with an increase in mortality in both men and women of all ages and ethnicities. “It will soon rival tobacco as the leading cause of preventable premature deaths,” said Dr. Sharaiha.

A new randomized control study which will compare ESG to diet and exercise has been approved and is now recruiting patients.

Dr. Sharaiha is a consultant for Apollo Endosurgery, Inc.

NewYork-Presbyterian

NewYork-Presbyterian is one of the nation’s most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and clinical innovation.

NewYork-Presbyterian has four major divisions: NewYork-Presbyterian Hospital is ranked #1 in the New York metropolitan area by U.S. News and World Report and repeatedly named to the magazine’s Honor Roll of best hospitals in the nation; NewYork-Presbyterian Regional Hospital Network is comprised of leading hospitals in and around New York and delivers high-quality care to patients throughout the region; NewYork-Presbyterian Physician Services connects medical experts with patients in their communities; and NewYork-Presbyterian Community and Population Health features the hospital’s ambulatory care network sites and operations, community care initiatives and healthcare quality programs, including NewYork Quality Care, established by NewYork-Presbyterian, Weill Cornell and Columbia.

NewYork-Presbyterian is one of the largest healthcare providers in the U.S. Each year, nearly 40,000 NewYork-Presbyterian professionals deliver exceptional care during more than 4 million patient visits.

For more information, visit www.nyp.org and find us on Facebook, Twitter and YouTube.

Weill Cornell Medicine

Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. The doctors and scientists of Weill Cornell Medicine—faculty from Weill Cornell Medical College, Weill Cornell Graduate School of Medical Sciences, and Weill Cornell Physician Organization—are engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Located in the heart of the Upper East Side’s scientific corridor, Weill Cornell Medicine’s powerful network of collaborators extends to its parent university Cornell University; to Qatar, where an international campus offers a U.S. medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide comprehensive patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian/Lower Manhattan Hospital and NewYork-Presbyterian/Queens. Weill Cornell Medicine is also affiliated with Houston Methodist. For more information, visit weill.cornell.edu.


Share on:
or:

Health news